Compare Upwork Inc (UPWK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upwork Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Upwork Inc trades at $9.18 (market cap $1.15B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 106× Upwork Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| UPWK | VRTX | |
|---|---|---|
Market Cap | $1.15B | $121.95B |
Sector | Industrials | Health |
52-Week High | $22.11 | $529.59 |
52-Week Low | $7.84 | $366.54 |
Enterprise Value | $952.17M | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UPWK trades at $9.19, up 1.43% today, with a bullish technical signal from moving averages. The company reported $788M revenue in 2025 with strong profitability margins (net income margin 13.81%) and attractive valuation ratios (P/E 11.52, P/S 1.64). Recent news highlights AI integration initiatives and Q2 2026 earnings anticipation, though legal investigations pose sentiment headwinds.
The outlook is cautiously optimistic with a $10.67 analyst price target suggesting 16% upside. Key opportunities include sustained revenue growth and AI-powered marketplace expansion, while risks involve earnings misses, legal overhangs, and competitive pressures in the gig economy space.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
